These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

591 related articles for article (PubMed ID: 27262711)

  • 1. Targeting the Tumor Environment in Squamous Cell Carcinoma of the Head and Neck.
    Schmitz S; Machiels JP
    Curr Treat Options Oncol; 2016 Jul; 17(7):37. PubMed ID: 27262711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting EGFR-PI3K-AKT-mTOR signaling enhances radiosensitivity in head and neck squamous cell carcinoma.
    Horn D; Hess J; Freier K; Hoffmann J; Freudlsperger C
    Expert Opin Ther Targets; 2015 Jun; 19(6):795-805. PubMed ID: 25652792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting pathways mediating resistance to anti-EGFR therapy in squamous cell carcinoma of the head and neck.
    Campbell NP; Hensing TA; Bhayani MK; Shaikh AY; Brockstein BE
    Expert Rev Anticancer Ther; 2016 Aug; 16(8):847-58. PubMed ID: 27400139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting cellular and molecular drivers of head and neck squamous cell carcinoma: current options and emerging perspectives.
    Ausoni S; Boscolo-Rizzo P; Singh B; Da Mosto MC; Spinato G; Tirelli G; Spinato R; Azzarello G
    Cancer Metastasis Rev; 2016 Sep; 35(3):413-26. PubMed ID: 27194534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microenvironment-driven intratumoral heterogeneity in head and neck cancers: clinical challenges and opportunities for precision medicine.
    Van den Bossche V; Zaryouh H; Vara-Messler M; Vignau J; Machiels JP; Wouters A; Schmitz S; Corbet C
    Drug Resist Updat; 2022 Jan; 60():100806. PubMed ID: 35121337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.
    Caponigro F; Di Gennaro E; Ionna F; Longo F; Aversa C; Pavone E; Maglione MG; Di Marzo M; Muto P; Cavalcanti E; Petrillo A; Sandomenico F; Maiolino P; D'Aniello R; Botti G; De Cecio R; Losito NS; Scala S; Trotta A; Zotti AI; Bruzzese F; Daponte A; Calogero E; Montano M; Pontone M; De Feo G; Perri F; Budillon A
    BMC Cancer; 2016 Nov; 16(1):918. PubMed ID: 27884140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HGF/Met Signaling in Head and Neck Cancer: Impact on the Tumor Microenvironment.
    Hartmann S; Bhola NE; Grandis JR
    Clin Cancer Res; 2016 Aug; 22(16):4005-13. PubMed ID: 27370607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecularly targeted agents and immunotherapy for the treatment of head and neck squamous cell cancer (HNSCC).
    Azoury SC; Gilmore RC; Shukla V
    Discov Med; 2016 Jun; 21(118):507-16. PubMed ID: 27448787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HER2 as a therapeutic target in head and neck squamous cell carcinoma.
    Pollock NI; Grandis JR
    Clin Cancer Res; 2015 Feb; 21(3):526-33. PubMed ID: 25424855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy in head and neck cancer: aiming at EXTREME precision.
    Szturz P; Vermorken JB
    BMC Med; 2017 Jun; 15(1):110. PubMed ID: 28571578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current Treatment Options for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
    Sacco AG; Cohen EE
    J Clin Oncol; 2015 Oct; 33(29):3305-13. PubMed ID: 26351341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy in Patients with Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck.
    Łasińska I; Kolenda T; Teresiak A; Lamperska KM; Galus Ł; Mackiewicz J
    Anticancer Agents Med Chem; 2019; 19(3):290-303. PubMed ID: 30198439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular targeted therapies in the management of head and neck squamous cell carcinoma: recent developments and perspectives.
    Bozec A; Peyrade F; Milano G
    Anticancer Agents Med Chem; 2013 Mar; 13(3):389-402. PubMed ID: 23092267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel Targeted Agents in Head and Neck Squamous Cell Carcinoma.
    Isaacsson Velho PH; Castro G; Chung CH
    Hematol Oncol Clin North Am; 2015 Dec; 29(6):993-1009. PubMed ID: 26568544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overview of Current Treatment Options and Investigational Targeted Therapies for Locally Advanced Squamous Cell Carcinoma of the Head and Neck.
    Zibelman M; Mehra R
    Am J Clin Oncol; 2016 Aug; 39(4):396-406. PubMed ID: 26967327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The hypoxic tumor microenvironment and drug resistance against EGFR inhibitors: preclinical study in cetuximab-sensitive head and neck squamous cell carcinoma cell lines.
    Boeckx C; Van den Bossche J; De Pauw I; Peeters M; Lardon F; Baay M; Wouters A
    BMC Res Notes; 2015 Jun; 8():203. PubMed ID: 26032726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging drugs for head and neck cancer.
    Wen Y; Grandis JR
    Expert Opin Emerg Drugs; 2015 Jun; 20(2):313-29. PubMed ID: 25826749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PDGF-AA mediates mesenchymal stromal cell chemotaxis to the head and neck squamous cell carcinoma tumor microenvironment.
    Watts TL; Cui R; Szaniszlo P; Resto VA; Powell DW; Pinchuk IV
    J Transl Med; 2016 Dec; 14(1):337. PubMed ID: 27931212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Taking a Full Snapshot of Cancer Biology: Deciphering the Tumor Microenvironment for Effective Cancer Therapy in the Oncology Clinic.
    Dzobo K
    OMICS; 2020 Apr; 24(4):175-179. PubMed ID: 32176591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting angiogenesis in head and neck cancer.
    Vassilakopoulou M; Psyrri A; Argiris A
    Oral Oncol; 2015 May; 51(5):409-15. PubMed ID: 25680863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.